Share >  
Share
Share on Tumblr

Uti Pharma Fund

News »

   latest by relevance
NAVs gained amid volatile markets
May 22, 2012 at 09:59 | Source: Moneycontrol.com
Equity and Balanced funds delivered a decent performance amid volatile markets. In the debt space both Long term and Short term continue to excel recording few decline.
Value buying emerging; IT, pharma good bet: Daiwa MF
May 16, 2012 at 18:01 | Source: CNBC-TV18
David Pezarkar of Daiwa Mutual Fund says that some value buying can be seen at the current level. With the weakening rupee IT stocks look attractive as an investment option. He also says that some Blue chip companies are showing are showing good value at this level.
Damani warns bad days to remain, bets on pharma & consumer
May 16, 2012 at 10:22 | Source: CNBC-TV18
The tough and bad days for Indian market are far from over. Foreign funds are eroding from India and experts warn that it is still indicating anemic symptoms. Ramesh Damani, Member, BSE is worried that the market is on a downtrend on the back of disappointing news and a modest amount of selling may push it further down.
NAVs advanced as markets snaps 5-day losing streak
May 16, 2012 at 09:38 | Source: Moneycontrol.com
Equity funds finally broke its losing spell after a gap of 5 sessions. The session ended with BSE gaining 112.41 points or 0.69%, to close at 16,328.25 while NSE went up 0.71% or 35 points to 4,942.80.
NAVs slips led by weak global and local cues
May 15, 2012 at 09:51 | Source: Moneycontrol.com
Equity funds yet again ended in a red zone for the fifth consecutive session led by weak market condition. The session ended with BSE losing 77.14 points or 0.47% at 16,215.84 while NSE was down by 21.10 points which close at 4,907.80.
NAVs slumped as markets ends lower
May 12, 2012 at 11:14 | Source: Moneycontrol.com
The downfall in the equity segment continued on account of weak market condition. The trading session ended with BSE benchmark falling 127.07 points or 0.77% at 16,292.98 and the NSE at 4,928.90 down by 36.80 points or 0.74%.

Videos »
Damani warns bad days to remain, bets on pharma & consumer
HDFC MF is CNBC-TV18's Fund House of the Year
Bombay HC rescues 20 MFs from clutches of I-T dept
16 MFs caught in crossfire with I-T dept over tax claims
Creapharm buy funded via internal accruals: Dishman Pharma
more »

Photos »

  /  
Related News »
Street to remain range-bound: UTI MF
Mostly, it will be range-bound," UTI MF executive vice-president and fund manager Swati Kulkarni told PTI in ... She added that sectors like FMCG, pharma and banking, among others, will do well in the current year. "Though valuations appear ...
May 15, 2012 at 12:55 | Source: in.com
Fund Manager
UTI Mutual Fund. In an exclusive interview with Varsha Inamdar, Sanjay Dongre further said, ``FMCG, pharma, automobile, IT and financials would continue to do well, while outlook for capital goods, metals, engineering is not favorable in the current environment.``
May 25, 2012 at 06:24 | Source: MyIris

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window